Scotiabank raises target for Pfizer stock from USD 30.00 to USD 33.00

Published on 10/07/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 15.03 billion in the second quarter of 2026, up 1.00 percent. Pfizer stock costs EUR 24.71 on October 7, 2026, versus EUR 24.41.

Fotorealistische unbeschriftete Pharma-Anlage bei Dämmerung, Symbolbild für Pfizer Inc — Fotorealistische Pharma-Produktionsanlage bei Dämmerung symbolisiert Pfizer Inc. mit ISIN US7170811035 im Biotech-Sektor, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at EUR 24.71 at Lang & Schwarz on October 7, 2026 at 3:03 p.m. CEST, plus 1.23 percent versus the prior close of EUR 24.41 on October 6, 2026. According to Pluang on October 6, 2026, Scotiabank raised its Pfizer price target from USD 30.00 to USD 33.00.

Scotiabank raises its target

The move lifts the target by 10.00 percent from USD 30.00, giving the analyst view a concrete comparison with Pfizer's recent valuation. The same report states that the target increase reflects confidence in Pfizer's future performance, while also noting that a price target is not a guarantee of market movement.

For investors, the key distinction is between the euro quotation used by German investors and Scotiabank's dollar target. The Lang & Schwarz quote gained 1.23 percent against its prior close, while the analyst action is a separate USD-based assessment.

Revenue grows in the second quarter

According to Fortune, Pfizer reported USD 15.00 billion of revenue in the second quarter of 2026, up 1.00 percent operationally year over year. Excluding COVID products, underlying revenue increased 5.00 percent operationally in the same period.

Adjusted diluted earnings per share reached USD 0.77 in the second quarter of 2026, while GAAP loss per share was USD 0.04. The contrast shows why Pfizer's adjusted outlook and its reported impairment charges need to be read separately.

Patent pressure remains measurable

Yahoo Finance reported on September 30, 2026 that Pfizer has more than USD 22.00 billion of 2025 revenue tied to drugs losing US exclusivity by 2028. The report also put Pfizer's cash dividend payout ratio at 89.00 percent on a trailing-twelve-month basis.

That counter-factor matters alongside the second-quarter growth figures: Pfizer is expanding its newer portfolio while preparing for a material loss-of-exclusivity burden. The 52-week range of USD 23.62 to USD 29.21 places the primary-market reference below its recent high.

Stock trades above its prior close

Pfizer was trading at EUR 24.71 at Lang & Schwarz on October 7, 2026 at 3:03 p.m. CEST, plus 1.23 percent versus the prior close of EUR 24.41 on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.